Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Empaveli
Pharma
Apellis reports 4% sales drop for eye disease med Syfovre
In a preliminary report of 2025 results, Apellis said that sales of its GA drug Syfovre came in at $587 million for the year, a 4% decline from 2024.
Kevin Dunleavy
Jan 12, 2026 1:06pm
Apellis snatches broad kidney disease expansion for Empaveli
Jul 28, 2025 8:00pm
Sobi places $300M bet on Empaveli in partnership with Apellis
Jul 1, 2025 11:28am
Apellis' Syfovre faces tough road ahead in GA market: analyst
May 14, 2025 11:10am
Novartis' Fabhalta nod in C3G leaves room for rival Apellis
Mar 21, 2025 10:37am
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Nov 5, 2024 3:41pm
